strekin hearing loss drug

Strekin Announces Completion of Patient Recruitment in Phase 3 Clinical Study of Hearing Loss Drug

BASEL, SWITZERLAND — Strekin AG, a biopharmaceutical company focused on treatments for hearing loss, announced that it has successfully completed patient recruitment in the RESTORE study, an international, randomized, placebo-controlled, Phase 3 clinical trial of the investigational drug STR001 in patients following a Sudden Sensorineural Hearing Loss (SSNHL) event. RESTORE is evaluating the ability of…

Read More
strekin hearing loss drug

Strekin AG Secures Financing to Complete Development of STR001 in Sudden Sensorineural Hearing Loss

BASEL, SWITZERLAND — Strekin AG, a clinical stage biopharmaceutical company, announced today that it has successfully closed a Series A financing round totaling CHF 2.82 Million (~$2.86M USD) from private investors. According to the announcement, the funds will enable Strekin to conclude its ongoing Phase 3 clinical trial of STR001 in Sudden Sensorineural Hearing Loss,…

Read More
strekin hearing loss drug

Swiss Biotech, Strekin, Secures Funding for Second Clinical Trial of Hearing Loss Drug

BASEL, SWITZERLAND — Strekin AG announced this week that it had successfully closed a Seed C financing round totaling CHF10 million (approximately $10.3 USD) from private investors. The latest financing round allows the company to conduct a second clinical trial of its leading drug candidate, STR001, as a potential new treatment for sudden sensorineural hearing…

Read More